Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Anemia 27Neoplasms 9Multiple Myeloma 7Leukemia 7Lymphoma 6Breast Neoplasms 6Neoplasms, Plasma Cell 5Lymphoma, Non-Hodgkin 4Precancerous Conditions 3Lymphoma, Follicular 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Prostatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Head and Neck Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1

Interventions

Epoetin Alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Red-Cell Aplasia, Pure × Epoetin Alfa × Clear all
NCT00246597 2011-05-19

A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer

Ortho Biotech Products, L.P.

Phase 3 Terminated
37 enrolled
BreastClassical hematology

Anemia, Breast Neoplasms, Red-Cell Aplasia, Pure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡